For the twelve months ended Sep 30, 2026, ProKidney Corp. reported $775.0K of revenue and -$103.28M of net income.
PROK revenueQ3 2026$174.0K
- Quarter YoY
- -19.8%
- QoQ
- +16.0%
- FY YoY
- 12x
PROK revenue was $174.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 19.8% from a year earlier and up 16.0% from the prior quarter. For the full fiscal 2025 it was $893.0K, up about 12-fold from fiscal 2024.
PROK net incomeQ3 2026-$35.59M
PROK net income was -$35.59M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$16.47M a year earlier. For the full fiscal 2025 it was -$68.99M, compared with -$61.19M in fiscal 2024.
PROK free cash flowQ3 2026-$39.88M
PROK free cash flow was -$39.88M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$31.79M a year earlier. For the full fiscal 2025 it was -$135.31M, compared with -$155.86M in fiscal 2024.
Source: XBRL data ProKidney Corp. files with the SEC, latest filing dated Nov 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.